AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 217 filers reported holding AMICUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $130,704,095 | -20.3% | 10,748,692 | -17.7% | 0.01% | -18.8% |
| Q2 2023 | $164,043,749 | -10.4% | 13,060,808 | -20.8% | 0.02% | -20.0% |
| Q1 2023 | $182,995,082 | -16.0% | 16,500,909 | -7.5% | 0.02% | -20.0% |
| Q4 2022 | $217,818,511 | +21.4% | 17,839,354 | +3.8% | 0.02% | +4.2% |
| Q3 2022 | $179,396,000 | -8.8% | 17,183,513 | -6.2% | 0.02% | -7.7% |
| Q2 2022 | $196,687,000 | +20.6% | 18,313,580 | +6.3% | 0.03% | +18.2% |
| Q1 2022 | $163,086,000 | +3.5% | 17,221,352 | +26.3% | 0.02% | +15.8% |
| Q4 2021 | $157,546,000 | +41.1% | 13,640,425 | +16.7% | 0.02% | +26.7% |
| Q3 2021 | $111,624,000 | -0.7% | 11,688,389 | +0.2% | 0.02% | 0.0% |
| Q2 2021 | $112,401,000 | +14.1% | 11,659,782 | +17.0% | 0.02% | +7.1% |
| Q1 2021 | $98,470,000 | -66.5% | 9,966,565 | -21.7% | 0.01% | -68.9% |
| Q4 2020 | $293,954,000 | +87.3% | 12,730,857 | +14.6% | 0.04% | +50.0% |
| Q3 2020 | $156,926,000 | +24.7% | 11,113,785 | +33.2% | 0.03% | +7.1% |
| Q2 2020 | $125,849,000 | +10.1% | 8,345,380 | -32.6% | 0.03% | -9.7% |
| Q1 2020 | $114,345,000 | -5.0% | 12,374,950 | +0.1% | 0.03% | +10.7% |
| Q4 2019 | $120,364,000 | +45.7% | 12,357,714 | +20.0% | 0.03% | +27.3% |
| Q3 2019 | $82,610,000 | +2.1% | 10,300,517 | +58.9% | 0.02% | 0.0% |
| Q2 2019 | $80,904,000 | +51.0% | 6,482,718 | +64.6% | 0.02% | +46.7% |
| Q1 2019 | $53,577,000 | +4.5% | 3,939,507 | -26.4% | 0.02% | 0.0% |
| Q4 2018 | $51,269,000 | -6.1% | 5,351,546 | +18.5% | 0.02% | +7.1% |
| Q3 2018 | $54,589,000 | -29.7% | 4,515,225 | -9.1% | 0.01% | -33.3% |
| Q2 2018 | $77,610,000 | +543.5% | 4,968,627 | +519.6% | 0.02% | +600.0% |
| Q1 2018 | $12,060,000 | -81.8% | 801,871 | -82.6% | 0.00% | -83.3% |
| Q4 2017 | $66,340,000 | -26.6% | 4,610,187 | -23.1% | 0.02% | -33.3% |
| Q3 2017 | $90,362,000 | +23.8% | 5,992,250 | -17.3% | 0.03% | +22.7% |
| Q2 2017 | $73,000,000 | -16.5% | 7,249,214 | -40.9% | 0.02% | +69.2% |
| Q1 2017 | $87,392,000 | +186.1% | 12,256,962 | +99.4% | 0.01% | +160.0% |
| Q4 2016 | $30,548,000 | +5901.6% | 6,146,884 | +8844.0% | 0.01% | – |
| Q3 2016 | $509,000 | +60.6% | 68,726 | +18.2% | 0.00% | – |
| Q2 2016 | $317,000 | +83.2% | 58,148 | +184.2% | 0.00% | – |
| Q1 2016 | $173,000 | -44.4% | 20,460 | -36.3% | 0.00% | – |
| Q4 2015 | $311,000 | -59.9% | 32,137 | -42.0% | 0.00% | – |
| Q3 2015 | $776,000 | +16.2% | 55,446 | +17.5% | 0.00% | – |
| Q2 2015 | $668,000 | -94.1% | 47,183 | -95.5% | 0.00% | -100.0% |
| Q1 2015 | $11,310,000 | +264.7% | 1,039,535 | +178.9% | 0.00% | +300.0% |
| Q4 2014 | $3,101,000 | -22.7% | 372,667 | -44.7% | 0.00% | -50.0% |
| Q3 2014 | $4,010,000 | +246.9% | 674,039 | +94.8% | 0.00% | – |
| Q2 2014 | $1,156,000 | +82.6% | 346,020 | +13.2% | 0.00% | – |
| Q1 2014 | $633,000 | -12.8% | 305,789 | -1.1% | 0.00% | – |
| Q4 2013 | $726,000 | -0.1% | 309,122 | -1.3% | 0.00% | – |
| Q3 2013 | $727,000 | +726.1% | 313,331 | +733.2% | 0.00% | – |
| Q2 2013 | $88,000 | – | 37,605 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |